KOREA PHARMA Co., Ltd.

KOSDAQ:A032300 Stock Report

Market Cap: ₩176.0b

KOREA PHARMA Past Earnings Performance

Past criteria checks 2/6

KOREA PHARMA's earnings have been declining at an average annual rate of -32.2%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 4.7% per year. KOREA PHARMA's return on equity is 4.2%, and it has net margins of 3.8%.

Key information

-32.2%

Earnings growth rate

-36.0%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate4.7%
Return on equity4.2%
Net Margin3.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is KOREA PHARMA (KOSDAQ:032300) A Risky Investment?

Nov 12
Is KOREA PHARMA (KOSDAQ:032300) A Risky Investment?

Optimistic Investors Push KOREA PHARMA Co., Ltd. (KOSDAQ:032300) Shares Up 29% But Growth Is Lacking

Oct 16
Optimistic Investors Push KOREA PHARMA Co., Ltd. (KOSDAQ:032300) Shares Up 29% But Growth Is Lacking

KOREA PHARMA (KOSDAQ:032300) Seems To Use Debt Quite Sensibly

Mar 26
KOREA PHARMA (KOSDAQ:032300) Seems To Use Debt Quite Sensibly

What You Need To Know About KOREA PHARMA Co., Ltd.'s (KOSDAQ:032300) Investor Composition

Jan 08
What You Need To Know About KOREA PHARMA Co., Ltd.'s (KOSDAQ:032300) Investor Composition

Revenue & Expenses Breakdown

How KOREA PHARMA makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A032300 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2479,7993,00025,5942,461
30 Jun 2480,4032,99525,6762,444
31 Mar 2483,1371,32726,1792,249
31 Dec 2383,2408426,5812,313
30 Sep 2384,549-2,43026,5212,114
30 Jun 2385,160-3,03026,3382,134
31 Mar 2382,782-1,59225,8992,212
31 Dec 2281,029-1,11925,0862,452
30 Sep 2281,5093,55024,9772,547
30 Jun 2280,3534,37224,6293,487
31 Mar 2280,2836,03524,8744,276
31 Dec 2179,5776,36824,3454,893
30 Sep 2175,0895,46823,6424,907
30 Jun 2174,3944,94922,6815,838
31 Mar 2172,8293,29721,5746,365
31 Dec 2071,5103,15921,6586,221
30 Sep 2069,8533,07521,9096,437
31 Mar 2066,4954,42622,1813,700
31 Dec 1966,1365,52822,1242,680
31 Dec 1860,4843,82819,7522,207
31 Dec 1756,0182,51420,42283
31 Dec 1653,702-14918,39226
31 Dec 1560,0584,34126,59346
31 Dec 1454,8295,24521,42541

Quality Earnings: A032300 has high quality earnings.

Growing Profit Margin: A032300 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A032300's earnings have declined by 32.2% per year over the past 5 years.

Accelerating Growth: A032300 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A032300 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).

Return on Equity

High ROE: A032300's Return on Equity (4.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:21
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KOREA PHARMA Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jongsun ParkEugene Investment & Securities Co Ltd.
Taehee KimMirae Asset Securities Co., Ltd.